GlassScriptPhysician profile
Amandeep Gill
NPI 1285838359
$5,974.61
in general payments reported to CMS, 2019-2025
47 companies · $1,162 in 2025
The $1,162 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,063 · 2020: $125 · 2021: $766 · 2022: $637 · 2023: $1,447 · 2024: $775 · 2025: $1,162.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,360 · Education: $23.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,359.55 |
| Education | $23.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $643.17 | 2019-2025 | |
| Janssen Biotech, INC. | $550.25 | 2019-2025 | Rybrevant, Akeega, Erleada |
| Merck Sharp & Dohme LLC | $507.59 | 2019-2025 | Keytruda, Keytruda Qlex, Welireg |
| Seagen INC. | $381.57 | 2019-2023 | Padcev |
| Amgen INC. | $278.38 | 2019-2023 | Nplate, Vectibix, Kyprolis |
| Pfizer INC. | $262.20 | 2019-2023 | |
| Monteris Medical Corporation | $248.39 | 2023-2025 | Neuroblate |
| Astrazeneca Pharmaceuticals LP | $242.82 | 2022-2025 | Imfinzi, Lynparza |
| Eisai INC. | $231.32 | 2021-2025 | |
| Kite Pharma, INC. | $193.52 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $192.78 | 2019-2025 | Opdivo |
| Celgene Corporation | $177.04 | 2019-2025 | Reblozyl |
| Gilead Sciences, INC. | $173.62 | 2023-2024 | Trodelvy |
| Abbvie INC. | $142.08 | 2023-2025 | |
| Astellas Pharma US INC | $130.83 | 2019-2025 | Padcev, Vyloy |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Gill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.